RT Generic
T1 Assessing the value of moderate‐to‐severe atopic dermatitis treatment using multi‐criteria decision analysis (MCDA)
A1 Pereyra-Rodriguez, Jose Juan
A1 Poveda, José Luis
A1 Rivero, Alvaro
A1 Serra-Baldrich, Esther
A1 Silvestre, Juan Francisco
A1 Armario-Hita, José Carlos
A1 Calleja, Miguel Angel
A1 Carrascosa, Jose Manuel
A1 Florez, Angeles
A1 Herranz, Pedro
A1 Comellas, Marta
A1 Ortiz de Frutos, Francisco Javier
K1 Atopic dermatitis
K1 Multi‑criteria decision analysis (MCDA)
K1 Health-related quality of life (HRQoL)
K1 Pruritus reduction
K1 Disease activity control
AB The increased understanding of atopic dermatitis (AD) pathophysiology has shed light on the underlying immunologic mechanisms and spurred the development of novel, more precisely targeted therapies. As new agents become available, assessing their added value is advisable. Yet the value of novel health interventions sometimes remains largely unmeasured and inadequately understood. Value assessment is challenging since it involves assessing the extent to which it meets current unmet needs. Therefore, it is necessary to establish the most relevant health outcomes from different stakeholders' perspectives.
PB Wiley
SN 0926-9959
YR 2024
FD 2024-01-01
LK https://hdl.handle.net/10668/28520
UL https://hdl.handle.net/10668/28520
LA en
NO Pereyra‐Rodríguez JJ, Poveda JL, Rivero A, Serra‐Baldrich E, Silvestre JF, Armario‐Hita JC et al. Assessing the value of moderate‐to‐severe atopic dermatitis treatment using multi‐criteria decision analysis (MCDA). JEADV 2024;38:e59‐e62
DS RISalud
RD Aug 6, 2025